Skip to content

PP&E (Net) at other companies

Amgen logo
AmgenAMGN
$8.22B+23.0%
Moderna logo
ModernaMRNA
$2.09B-5.7%
Immunovant, Inc. logo
Immunovant, Inc.IMVT
$443K-47.5%
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$7.66B+6.2%
AbbVie logo
AbbVieABBV
$5.69B+8.6%
Regenxbio logo
RegenxbioRGNX
$101.87M-11.0%

Other financials

Income statement

See full
Revenue$2.5M-66.7%
Operating income-$339.2M-23.6%
Net income-$265.9M-257%
EPS (diluted)-$0.38-265%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$25.25B+226%
Enterprise value$23.93B+209%
P/S3,056.5×+2,723×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-9,183.5%-17,093pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: Roivant Sciences’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's PP&E (net)?
Roivant Sciences (ROIV) reported PP&E (net) of $11.99M in Q1 2026.
How has Roivant Sciences's PP&E (net) changed year-over-year?
Roivant Sciences's PP&E (net) decreased by 0.6% year-over-year, from $12.06M to $11.99M.
What is the long-term trend for Roivant Sciences's PP&E (net)?
Over 5 years (2020 to 2025), Roivant Sciences's PP&E (net) has grown at a -4.1% compound annual growth rate (CAGR), from $14.75M to $11.99M.
What does PP&E (net) mean?
Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.